key: cord-0804276-zcwh1892
authors: Cho, Alice; Muecksch, Frauke; Schaefer-Babajew, Dennis; Wang, Zijun; Finkin, Shlomo; Gaebler, Christian; Ramos, Victor; Cipolla, Melissa; Mendoza, Pilar; Agudelo, Marianna; Bednarski, Eva; DaSilva, Justin; Shimeliovich, Irina; Dizon, Juan; Daga, Mridushi; Millard, Katrina; Turroja, Martina; Schmidt, Fabian; Zhang, Fengwen; Tanfous, Tarek Ben; Jankovic, Mila; Oliveria, Thiago Y.; Gazumyan, Anna; Caskey, Marina; Bieniasz, Paul D.; Hatziioannou, Theodora; Nussenzweig, Michel C.
title: Anti- SARS-CoV-2 Receptor Binding Domain Antibody Evolution after mRNA Vaccination
date: 2021-08-30
journal: bioRxiv
DOI: 10.1101/2021.07.29.454333
sha: 4bd9965a6036edaa12099af9f9877736b93ea1c5
doc_id: 804276
cord_uid: zcwh1892

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection produces B-cell responses that continue to evolve for at least one year. During that time, memory B cells express increasingly broad and potent antibodies that are resistant to mutations found in variants of concern1. As a result, vaccination of coronavirus disease 2019 (COVID-19) convalescent individuals with currently available mRNA vaccines produces high levels of plasma neutralizing activity against all variants tested1, 2. Here, we examine memory B cell evolution 5 months after vaccination with either Moderna (mRNA-1273) or Pfizer- BioNTech (BNT162b2) mRNA vaccines in a cohort of SARS-CoV-2 naïve individuals. Between prime and boost, memory B cells produce antibodies that evolve increased neutralizing activity, but there is no further increase in potency or breadth thereafter. Instead, memory B cells that emerge 5 months after vaccination of naïve individuals express antibodies that are similar to those that dominate the initial response. While individual memory antibodies selected over time by natural infection have greater potency and breadth than antibodies elicited by vaccination, the overall neutralizing potency of plasma is greater following vaccination. These results suggest that boosting vaccinated individuals with currently available mRNA vaccines will increase plasma neutralizing activity but may not produce antibodies with breadth equivalent to those obtained by vaccinating convalescent individuals.

obtained at 2 or 3 time points. Individuals indicated as "prime" were sampled an average of 2.5 42 weeks after receiving their first vaccine dose. Individuals who completed their vaccination 43 regimen were sampled after an average of 1.3 months after the boost (median=35.5 days) which 44

is not statistically different from the 1.3 month sampling in our naturally infected cohort 3 45 (median=38.5 days, p=0.21). Individuals sampled at 1.3 months were sampled again 46 approximately 5 months after the second vaccine dose. The volunteers ranged in age from 23-78 47 years (median=34.5 years), 53% were male and 47% female (for details see Methods and 48

Supplementary Tables 1 and 2). 49 50

Plasma IgM, IgG, and IgA responses to SARS-CoV-2 receptor binding domain (RBD) were 52 measured by enzyme linked immunosorbent assay (ELISA) 3 . As reported by others 2,4-6 there was 53 a significant increase in IgG reactivity to RBD between prime and boost (p<0.0001, Fig. 1a) . 54

IgM and IgA titers were lower than IgG titers and remained low after the second vaccine dose 55 (Extended data Fig. 1a and b) . The magnitude of the response was inversely correlated with age 56 after the prime (r=-0.54, p=0.005), but in this limited sample set the age difference was no longer 57 significant at 1.3 or 5 months after the second vaccine dose (Fig. 1b , Extended data Fig. 1c) . Extended data Fig. 1a and b) . 62 63 We also compared the affinities of pairs of antibodies obtained from persisting clones between 199 1.3 and 5 months after vaccination. Persisting clones obtained at 1.3 and 5 months from 200 vaccinated individuals showed a median 4.5-fold increase in affinity (p<0.0001, Fig. 4b ).

In 201 contrast, a comparable group of persisting clonal antibodies obtained from convalescent 202 individuals 1.3 and 6.2 months after infection showed a median 11.2-fold increase in affinity 203 (p=0.002, Fig. 4b) . 204 205

To determine whether the epitopes targeted by the monoclonal antibodies were changing over 206 time, we performed BLI experiments in which a preformed antibody-RBD complex was exposed 207 to a second monoclonal targeting one of 4 classes of structurally defined epitopes 1,3 (see 208 schematic in Extended data Fig. 8a ). There was no significant change in the distribution of 209 targeted epitopes among 52 randomly selected antibodies with comparable neutralizing activity 210 obtained from the 1.3-and 5-month time points (Extended Data Fig. 8b and c, and Extended 211 Data Fig. 9) . 212 213

In addition to the increase in potency, the neutralizing breath of memory antibodies obtained 214 from persisting clones from convalescent individuals increases with time after infection 1,7,25 . To 215 determine whether there is a similar increase in breadth with time after vaccination, we selected 216 20 random antibodies from the prime or 1.3 months after boost, with representative levels of 217 activity against the original Wuhan Hu-1 strain, and measured their neutralization potency 218 against a panel of pseudotypes encoding RBD mutations which were selected for resistance to 219 different RBD antibody classes and/or are associated with circulating variants of concern 220 (Extended data. Fig. 10 ). There was little change in breadth between prime and 1.3 months after 221 boost, with only a small increase in resistance to K417N Circulating antibodies are produced by an initial burst of short-lived plasmablasts 26-28 , and 238 maintained by plasma cells with variable longevity 29-32 . SARS-CoV-2 infection or mRNA 239 vaccination produces an early peak antibody response that decreases by 5-10-fold after 5 240 months 7,33-37 . Notably, neutralization titres elicited by vaccination exceed those of COVID-19 241 recovered individuals at all comparable time points assayed. Nevertheless, neutralizing potency 242 against variants is significantly lower than against Wuhan Hu-1, with up to 5-10-fold reduced 243 activity against the B.1.351 variant 5,6,13,14,38 . Taken together with the overall decay in 244 neutralizing activity there can be 1-2 orders of magnitude decrease in serum neutralizing activity 245 after 5 or 6 months against variants when compared to the peak of neutralizing activity against 246

Wuhan Hu-1. Thus, antibody mediated protection against variants is expected to wane 247 significantly over a period of months, consistent with reports of reinfection in convalescent 248 The memory response would be expected to protect individuals that suffer breakthrough 256 infection from developing serious disease. Both natural infection and mRNA vaccination 257 produce memory antibodies that evolve increased affinity. However, vaccine-elicited memory 258 monoclonal antibodies show more modest neutralizing potency and breadth than those that 259 developed after natural infection 1,7 . Notably, the difference between the memory compartment 260 that develops in response to natural infection vs mRNA vaccination reported above is consistent 261 with the higher level of protection from variants conferred by natural infection 42 . 262

There are innumerable differences between natural infection and mRNA vaccination that could 264 account for the differences in antibody evolution over time. These include but are not limited to: 265 1. Route of antigen delivery, respiratory tract vs. intra-muscular injection 48,49 ; 2. The physical 266 nature of the antigen, intact virus vs. conformationally stabilized prefusion S protein 50 ; 3. 267

Antigen persistence, weeks in the case of natural infection 7 vs. hours to days for mRNA 51 . Each 268 of these could impact on B cell evolution and selection directly, and indirectly through 269 differential T cell recruitment. showing increased breadth remains to be determined. Finally, timing an additional boost for 281 optimal responses depends on whether the objective is to prevent infection or disease 53 . Given 282 the current rapid emergence of SARS-CoV-2 variants, boosting to prevent infection would likely 283 be needed on a time scale of months. The optimal timing for boosting to prevent serious disease 284 will depend on the stability and further evolution of the memory B cell compartment. CoV-2 RBD after prime, and 1.3 months (m) and 5 months (m) post-second vaccination for n=32 291 paired samples. Samples without a prime value are shown in black (n=6). b, Graph shows plasma 292

IgG antibody binding (AUC, Y-axis) plotted against age (X-axis) after prime (black), and 1.3 293 months (orange) and 5 months (green) post-second vaccination. c, Graph shows AUC values from 294 a (Y-axis) plotted against time after vaccination (X-axis). Samples without a prime value are 295 shown in black. d, NT50 values in pre-pandemic plasma (ctr) as well as plasma from convalescent 296 individuals 1.3m 3 and 6.2m 7 after infection (grey) and in n=32 vaccinated individuals after prime, 297 and 1.3-and 5-months after receiving 2 doses of an mRNA vaccine. Samples without a prime 298 variants of interest/concern (n=15 paired samples at 1.3-and 5-months after full vaccination). The E484K, K417N/E484K/N501Y, L452R/E484Q and L452R/T478K substitution, as well as 464 the deletions/substitutions corresponding to variants of concern listed above were incorporated 465 into a spike protein that also includes the R683G substitution, which disrupts the furin cleaveage 466 site and increases particle infectivity. Neutralizing activity against mutant pseudoviruses were 467 Antibodies were identified and sequenced as described previously 3,59 . In brief, RNA from single 525 cells was reverse-transcribed (SuperScript III Reverse Transcriptase, Invitrogen, 18080-044) and 526 the cDNA was stored at −20 °C or used for subsequent amplification of the variable IGH, IGL 527 and IGK genes by nested PCR and Sanger sequencing. Sequence analysis was performed using 528

MacVector. Amplicons from the first PCR reaction were used as templates for sequence-and 529 ligation-independent cloning into antibody expression vectors. Recombinant monoclonal 530 antibodies were produced and purified as previously described 3 . 531 532

Biolayer interferometry assays were performed as previously described 3 . Briefly, we used the 

Antibody sequences were trimmed based on quality and annotated using Igblastn v.1.14. with 547 IMGT domain delineation system. Annotation was performed systematically using Change-O 548 toolkit v.0.4.540 60 . Heavy and light chains derived from the same cell were paired, and 549 clonotypes were assigned based on their V and J genes using in-house R and Perl scripts. All 550 scripts and the data used to process antibody sequences are publicly available on GitHub 551 (https://github.com/stratust/igpipeline/tree/igpipeline2_timepoint_v2). Fig. 2 : Flow Cytometry. a, Gating strategy for phenotyping. Gating was on 636 singlets that were CD19 + or CD20 + and CD3-CD8-CD16-Ova-. Anti-IgG, IgM, IgA, IgD, CD71 637 and CD27 antibodies were used for B cell phenotype analysis. Antigen-specific cells were detected 638 

Schematic 736 representation of the BLI experiment for randomly selected antibodies isolated from vaccinees 737 1.3-and 5 months after full vaccination (each presented group shows n=26 antibodies). b. Heat-738 map of relative inhibition of Ab2 binding to the preformed Ab1-RBD complexes (grey=no 739 binding, yellow=low binding, orange=intermediate binding, red=high binding). Values are 740 normalized through the subtraction of the autologous antibody control

Pie charts indicate the fraction of antibodies that are assigned to different 742 classes according to their binding pattern as shown in b and Extended data Fig. 9

Naturally enhanced neutralizing breadth against SARS-CoV-2 one year 762 after infection

Distinct antibody and memory B cell responses in SARS-CoV-2 naive and 764 recovered individuals following mRNA vaccination

Convergent antibody responses to SARS-CoV-2 in convalescent 767 individuals

Altered cellular and humoral immune responses following SARS-769

CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. 770 medRxiv

Memory B cells control SARS-CoV-2 variants upon mRNA vaccination of 772 naive and COVID-19 recovered individuals. bioRxiv

SARS-CoV-2 mRNA vaccines induce persistent human germinal centre 775 responses

Evolution of antibody immunity to SARS-CoV-2

Measuring SARS-CoV-2 neutralizing antibody activity using 779 pseudotyped and chimeric viruses

Interim Estimates of Vaccine Effectiveness of Pfizer-BioNTech and 781

Moderna COVID-19 Vaccines Among Health Care Personnel -33 U.S. Sites

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta)

SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies 787 to NTD, RBD, and S2

Prior SARS-CoV-2 infection rescues B and T cell responses to 789 variants after first vaccine dose

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. 791

mRNA vaccination boosts cross-variant neutralizing antibodies 793 elicited by SARS-CoV-2 infection

Detection and characterization of the SARS-CoV-2 lineage B.1.526 in 795 New York. bioRxiv

Infection and Vaccine-Induced Neutralizing-Antibody Responses to the 797 SARS-CoV-2 B.1.617 Variants

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody 799 neutralization

Profiling B cell immunodominance after SARS-CoV-2 infection reveals 803 antibody evolution to non-neutralizing viral targets

In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and 806 neutralizing antibodies

Potent neutralizing antibodies from COVID-19 patients define 809 multiple targets of vulnerability

Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing 812 Antibodies from COVID-19 Patients

Analysis of a SARS-CoV-2-Infected Individual Reveals Development of 815 Potent Neutralizing Antibodies with Limited Somatic Mutation

Humoral immunity. Apoptosis and 818 antigen affinity limit effector cell differentiation of a single naive B cell

Affinity maturation of SARS-CoV-2 neutralizing antibodies confers 821 potency, breadth, and resilience to viral escape mutations

Pandemic H1N1 influenza vaccine induces a recall response in humans 824 that favors broadly cross-reactive memory B cells

Rapid and massive virus-specific plasmablast responses during acute 827 dengue virus infection in humans

Rapid cloning of high-affinity human monoclonal antibodies against 830 influenza virus

Duration of humoral immunity to common 832 viral and vaccine antigens

Influenza vaccine-induced human bone marrow plasma cells decline 835 within a year after vaccination

Long-Lived Plasma Cells Are Contained within the

CD38(hi)CD138(+) Subset in Human Bone Marrow

Humoral immunity due to long-lived 841 plasma cells

Immunological memory to SARS-CoV-2 assessed for up to 8 months 843 after infection

Prolonged evolution of the human B cell response to SARS-CoV-2 845 infection

Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination

Robust neutralizing antibodies to SARS-CoV-2 infection persist for 849 months

Durability of mRNA-1273-induced antibodies against SARS-CoV-2 variants

Resistance of SARS-CoV-2 variants to neutralization by monoclonal and 853 serum-derived polyclonal antibodies

& National Study Group for

Vaccine Breakthrough Infections with SARS-CoV-2 Variants

Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care 861 Workers

Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: 863 reinfections versus breakthrough infections. medRxiv

Class-866 switched memory B cells remodel BCRs within secondary germinal centers

Restricted Clonality and Limited Germinal Center Reentry Characterize 869

Different B cell 872 populations mediate early and late memory during an endogenous immune response

Maturation and persistence of the anti-SARS-CoV-2 memory B cell 877 response

An adenovirus-vectored COVID-19 vaccine confers protection from SARS-879 COV-2 challenge in rhesus macaques

A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower 882 Respiratory Tracts against SARS-CoV-2

Antibodies elicited by mRNA-1273 vaccination bind more broadly to 885 the receptor binding domain than do those from SARS-CoV-2 infection

Expression kinetics of nucleoside-modified mRNA delivered in lipid 888 nanoparticles to mice by various routes

Preliminary Analysis of Safety and Immunogenicity of a SARS-CoV-2 Variant 891 Vaccine Booster. medRxiv

Neutralizing antibody levels are highly predictive of immune 894 protection from symptomatic SARS-CoV-2 infection

A new coronavirus associated with human respiratory disease in China

A serological assay to detect SARS-CoV-2 seroconversion in humans

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with 901 COVID-19 Disease and Unexposed Individuals

Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal 904 Common Epitopes and Recurrent Features of Antibodies

Escape from neutralizing antibodies by SARS-CoV-2 spike protein 907 variants

Enhanced SARS-CoV-2 neutralization by dimeric IgA

Change-O: a toolkit for analyzing large-scale B cell immunoglobulin 911 repertoire sequencing data

High frequency of shared clonotypes in human B cell receptor repertoires. 914

Antibody Repertoires for Exploring Antibody Diversity and Predicting Antibody 917 Prevalence